Analystreport

Xeris Biopharma (NASDAQ:XERS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Xeris Biopharma Holdings, Inc.  (XERS) 
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am Check Earnings Report